Global: Vaccine 'slashes TB infection' in HIV patients

A new candidate vaccine can significantly reduce rates of tuberculosis (TB) infection in HIV-positive individuals, according to researchers. The results of the seven-year Phase III 'DarDar' trial in Dar-es-Salaam, Tanzania, were presented at the 39th Union World Conference on Lung Health in Paris, France, this week (20 October). This is the first successful demonstration of any protective effect against TB in HIV/AIDS patients.